Production (Stage)
Cue Biopharma, Inc.
CUE
$0.602
-$0.0337-5.30%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -73.29% | -52.76% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -73.29% | -52.76% | |||
| Cost of Revenue | -21.84% | 15.36% | |||
| Gross Profit | 11.96% | -59.53% | |||
| SG&A Expenses | 257.00% | -62.28% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 13.52% | -8.52% | |||
| Operating Income | -27.73% | -8.05% | |||
| Income Before Tax | -29.08% | -9.65% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -29.08% | -9.65% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -29.08% | -9.65% | |||
| EBIT | -27.73% | -8.05% | |||
| EBITDA | -27.98% | -8.17% | |||
| EPS Basic | -29.09% | 24.32% | |||
| Normalized Basic EPS | -29.16% | 25.19% | |||
| EPS Diluted | -29.09% | 24.32% | |||
| Normalized Diluted EPS | -29.16% | 25.19% | |||
| Average Basic Shares Outstanding | 0.02% | 44.91% | |||
| Average Diluted Shares Outstanding | 0.02% | 44.91% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||